Landscape Capital Management L.L.C. Makes New $585,000 Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Landscape Capital Management L.L.C. acquired a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 6,513 shares of the company's stock, valued at approximately $585,000.

Several other hedge funds also recently bought and sold shares of the business. Intech Investment Management LLC purchased a new stake in shares of Axsome Therapeutics during the third quarter valued at $983,000. Moors & Cabot Inc. purchased a new stake in Axsome Therapeutics in the 3rd quarter valued at about $200,000. B. Metzler seel. Sohn & Co. Holding AG bought a new position in Axsome Therapeutics in the 3rd quarter worth about $830,000. Whalen Wealth Management Inc. purchased a new position in shares of Axsome Therapeutics during the third quarter worth approximately $236,000. Finally, Royce & Associates LP raised its stake in shares of Axsome Therapeutics by 73.1% during the third quarter. Royce & Associates LP now owns 22,500 shares of the company's stock valued at $2,022,000 after acquiring an additional 9,500 shares in the last quarter. Institutional investors own 81.49% of the company's stock.

Axsome Therapeutics Stock Up 0.5 %

Shares of AXSM stock traded up $0.49 during trading hours on Friday, reaching $98.68. 427,245 shares of the company's stock were exchanged, compared to its average volume of 557,234. Axsome Therapeutics, Inc. has a 1 year low of $60.28 and a 1 year high of $105.00. The company has a current ratio of 2.44, a quick ratio of 2.37 and a debt-to-equity ratio of 1.97. The stock has a market cap of $4.78 billion, a PE ratio of -15.11 and a beta of 1.26. The stock's fifty day moving average price is $90.99 and its two-hundred day moving average price is $85.06.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share for the quarter, topping the consensus estimate of ($1.38) by $0.04. The company had revenue of $104.76 million for the quarter, compared to the consensus estimate of $98.71 million. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. During the same quarter in the previous year, the firm earned ($1.32) EPS. Research analysts predict that Axsome Therapeutics, Inc. will post -4.75 EPS for the current year.

Insider Activity

In related news, Director Mark E. Saad sold 11,016 shares of Axsome Therapeutics stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $91.31, for a total transaction of $1,005,870.96. Following the completion of the sale, the director now owns 10,002 shares of the company's stock, valued at $913,282.62. The trade was a 52.41 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 22.40% of the company's stock.

Wall Street Analysts Forecast Growth

AXSM has been the topic of several research analyst reports. HC Wainwright reissued a "buy" rating and issued a $180.00 price objective on shares of Axsome Therapeutics in a research note on Thursday, September 5th. StockNews.com raised shares of Axsome Therapeutics from a "sell" rating to a "hold" rating in a research note on Wednesday. UBS Group dropped their target price on shares of Axsome Therapeutics from $107.00 to $105.00 and set a "buy" rating on the stock in a report on Tuesday, August 6th. Bank of America raised shares of Axsome Therapeutics from a "neutral" rating to a "buy" rating and upped their price target for the stock from $95.00 to $106.00 in a research report on Tuesday, August 6th. Finally, Wells Fargo & Company started coverage on shares of Axsome Therapeutics in a report on Tuesday, September 3rd. They set an "overweight" rating and a $140.00 price objective on the stock. One analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $124.93.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.